Pericardial Fluid Analysis in Diagnosis and Prognosis of Patients Who Underwent Pericardiocentesis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 03 12 2022
revised: 16 03 2023
accepted: 18 04 2023
medline: 13 6 2023
pubmed: 22 5 2023
entrez: 21 5 2023
Statut: ppublish

Résumé

In this study, we aimed to examine the diagnostic yield of pericardial fluid biochemistry and cytology and their prognostic significance in patients with percutaneously drained pericardial effusions, with and without malignancy. This is a single-center, retrospective study of patients who underwent pericardiocentesis between 2010 and 2020. Data were extracted from electronic patient records, including procedural information, underlying diagnosis, and laboratory results. Patients were grouped into those with and without underlying malignancy. A Cox proportional hazards model was used to analyze the association of variables with mortality. The study included 179 patients; 50% had an underlying malignancy. There were no significant differences in pericardial fluid protein and lactate dehydrogenase between the 2 groups. Diagnostic yield from pericardial fluid analysis was greater in the malignant group (32% vs 11%, p = 0.002); 72% of newly diagnosed malignancies had positive fluid cytology. The 1-year survival was 86% and 33% in nonmalignant and malignant groups, respectively (p <0.001). Of 17 patients who died within the nonmalignant group, idiopathic effusions were the largest group (n = 6). In malignancy, lower pericardial fluid protein and higher serum C-reactive protein were associated with increased risk of mortality. In conclusion, pericardial fluid biochemistry has limited value in determining the etiology of pericardial effusions; fluid cytology is the most important diagnostic test. Mortality in malignant pericardial effusions may be associated with lower pericardial fluid protein levels and a higher serum C-reactive protein. Nonmalignant pericardial effusions do not have a benign prognosis and close follow-up is required.

Identifiants

pubmed: 37210977
pii: S0002-9149(23)00248-5
doi: 10.1016/j.amjcard.2023.04.034
pii:
doi:

Substances chimiques

C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-87

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to declare.

Auteurs

Andrew Sullivan (A)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom. Electronic address: andrew.sullivan@nhs.net.

Adam S C Dennis (ASC)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.

Krishnaraj Rathod (K)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom.

Daniel Jones (D)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom.

Stefania Rosmini (S)

King's College Hospital NHS Trust Foundation, London, United Kingdom.

Charlotte Manisty (C)

Institute of Cardiovascular Science, University College London, London, United Kingdom; Department of Cardiac Imaging, St Bartholomew's Hospital, London, United Kingdom.

Sanjeev Bhattacharyya (S)

Department of Cardiac Imaging, St Bartholomew's Hospital, London, United Kingdom.

Vanessa Foggo (V)

Department of Haematology, St Bartholomew's Hospital, London, United Kingdom.

John Conibear (J)

Department of Oncology, St Bartholomew's Hospital, London, United Kingdom.

Tat Koh (T)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom.

Paul Rees (P)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom.

Mick Ozkor (M)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom.

Catherine Clare Thornton (CC)

Department of Rheumatology, University College London Hospital, London, United Kingdom.

Constantinos O'Mahony (C)

Department of Interventional Cardiology, St Bartholomew's Hospital, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH